Israeli TailorMed sold for about $250 million

Israeli company TailorMed, which developed a system to help patients in the US finance medical treatments, is being sold to GrowthCurve Capital for about $250 million. The deal constitutes an exit for most of the company's investors, including Israeli entities. The company will continue to operate with its current management and development center in Tel Aviv.

Israeli company TailorMed is being sold to private equity firm GrowthCurve Capital at a valuation of about $250 million. The deal constitutes an exit for most of the company's investors, including TriVentures, Accelmed, Bridges, Samsung Next, Discount Capital, and publicly traded Almeda. The company, founded in 2016 by Shmulik Dvorsky and Adam Sitbon, developed a system that identifies assistance programs for purchasing medications and treatments for patients in the US. The system is implemented in approximately 950 hospitals and 4,700 clinics, connecting patients to about 6,000 support programs. The company will continue to operate under the fund with its current management, maintain its development center in Tel Aviv, and is expected to make additional acquisitions. Founder Dvorsky stated, "What happened to us basically shouldn't have happened."